文献速递糖尿病

2005-2007年与2015-2017年美国糖尿病降糖药物国家支出增长的因素分析

Factors Contributing to the Rising National Cost of Glucose-Lowering Medicines for Diabetes During 2005-2007 and 2015-2017.
PubMed 文献 · Diabetes Care · 2020-07-31

基于医疗支出面板调查,分析2005-2007年与2015-2017年成人糖尿病降糖药物支出的变化,并按药物类别分解用户数与人均成本的贡献。胰岛素支出增加主要与类似物支出上升(156%)相关,非胰岛素支出增加是较新药物成本上升(+88%)与较老药物成本下降(-34%)的净效应。

要点

  • 胰岛素支出增加主要与类似物支出上升(156%)相关,大部分来自人均成本增加。
  • 非胰岛素支出增加是较新药物成本上升(+88%)与较老药物成本下降(-34%)的净效应,多数组用户数增加贡献大于人均成本。

核心结论

  • 过去十年降糖药物国家支出增加主要与胰岛素(尤其是类似物)和较新非胰岛素药物成本上升相关,人均成本的影响大于用户数。
  • 理解支出增长的因素有助于寻找遏制成本增长的途径。

研究设计与样本

  • 使用医疗支出面板调查,估计2005-2007年与2015-2017年≥18岁糖尿病成人降糖药物支出的变化。
  • 按药物组分解总支出增加:胰岛素按人胰岛素和类似物;非胰岛素按二甲双胍、较老、较新和复方药物。
  • 对每组量化用户数和人均成本的贡献,成本以2017年美元计。

主要发现

  • 胰岛素支出增加主要与类似物支出上升(156%)相关。
  • 非胰岛素支出增加是较新药物成本上升(+88%)与较老药物成本下降(-34%)的净效应。
  • 胰岛素支出增加大部分来自人均成本增加;多数非胰岛素组用户数增加贡献大于人均成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We examined changes in glucose-lowering medication spending and quantified the magnitude of factors that are contributing to these changes. RESEARCH DESIGN AND METHODS: Using the Medical Expenditure Panel Survey, we estimated the change in spending on glucose-lowering medications during 2005-2007 and 2015-2017 among adults aged ≥18 years with diabetes. We decomposed the increase in total spending by medication groups: for insulin, by human and analog; and for noninsulin, by metformin, older, newer, and combination medications. For each group, we quantified the contributions by the number of users and cost-per-user. Costs were in 2017 U.S. dollars. RESULTS: National spending on glucose-lowering medications increased by $40.6 billion (240%), of which insulin and noninsulin medications contributed $28.6 billion (169%) and $12.0 billion (71%), respectively. For insulin, the increase was mainly associated with higher expenditures from analogs (156%). For noninsulin, the increase was a net effect of higher cost for newer medications (+88%) and decreased cost for older medications (-34%). Most of the increase in insulin spending came from the increase in cost-per-user. However, the increase in the number of users contributed more than cost-per-user in the rise of most noninsulin groups. CONCLUSIONS: The increase in national spending on glucose-lowering medications during the past decade was mostly associated with the increased costs for insulin, analogs in particular, and newer noninsulin medicines, and cost-per-user had a larger effect than the number of users. Understanding the factors contributing to the increase helps identify ways to curb the growth in costs.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Zhou X, Shrestha SS, Shao H, et al. Factors Contributing to the Rising National Cost of Glucose-Lowering Medicines for Diabetes During 2005-2007 and 2015-2017. Diabetes Care. 2020. PMID: 32737138. doi:10.2337/dc19-2273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。